Other Clinical Trial - Extended IASD Investigation: REDUCE LAP-HF IV

Status Withdrawn

Clinical Trial Summary

Multicenter, Prospective, Open Label, Single Arm, Clinical Trial. The primary objective of this clinical trial is to further evaluate the safety and clinical efficacy of the IASD System II in symptomatic heart failure patients with an left ventricular ejection fraction (LVEF) ≥ 40%, and elevated left sided filling pressures despite standard Guideline Directed Medical Therapy (GDMT); and to compare the safety and efficacy results to those from the treatment arm of the REDUCE LAP-HF Randomized Trial II (Corvia protocol 1601).

Clinical Trial Description

Participants are screened against non-invasive eligibility criteria and scheduled for a hemodynamic evaluation. Following right heart catheterization at rest and during supine bicycle exercise, patients will undergo a brief intracardiac echocardiography (ICE) or transesophageal echocardiography (TEE) exam for septal suitability. Eligible patients continue with, fluoroscopically and echo guided transseptal puncture and IASD System II implant procedure. If a previously unknown protocol exclusion is discovered during the index procedure, and device is not implanted, participant is followed for 30 days, and then exits the study. Participants return for follow-up exams 30 days after the implant procedure and annually for 5 years after the implant procedure. In-person visits will take place for the first 2 years. Telephone follow-up and medical chart review will be conducted for years 3-5. ;

Study Design

Related Conditions & MeSH terms

Heart Failure
Heart Failure With Mid Range Ejection Fraction
Heart Failure With Preserved Ejection Fraction

Clinical Trial Details

NCT number	NCT04632160
Study type	Interventional
Source	Corvia Medical
Contact
Status	Withdrawn
Phase	N/A
Start date	December 1, 2021
Completion date	January 1, 2027

View Details

See also
Status	Clinical Trial	Phase
Suspended	`NCT05839730` - Fast Induced Remodeling in Heart Failure With Preserved Ejection Fraction	N/A
Recruiting	`NCT05095688` - Relationship Between Adipose Tissue Distribution and Arterial Stiffness in HFpEF
Recruiting	`NCT06379152` - Effect of Bilirubin on Prognosis in Heart Failure With Preserved Ejection Fraction
Recruiting	`NCT05676684` - Dapagliflozin, Spironolactone or Both for HFpEF	Phase 2/Phase 3
Recruiting	`NCT04153136` - Effects of Sacubitril/Valsartan on Subclinical Heart Failure in HIV (The ENCHANTMENT HIV Study)	Phase 2
Recruiting	`NCT06114498` - Hospital Register of Decompensated Heart Failure With Preserved Ejection Fraction
Recruiting	`NCT05715697` - Renal Denervation in Patients With Chronic Heart Failure With Preserved Ejection Fraction	N/A
Recruiting	`NCT04745013` - PeRsonalIzed remOtely Guided Preventive exeRcIse Therapy for a healThY Heart	N/A
Completed	`NCT05126836` - Cilostazol for HFpEF	Phase 2
Completed	`NCT05586828` - A Single-center Retrospective Cohort Study to Explore the Prognostic Significance of CONUT in Elderly CAD Patients With HFpEFand Compare CONUT With Other Objective Nutritional Indices.
Recruiting	`NCT04594499` - The Relationship Between Pericardial Fat Thickness and Arterial Stiffness in HFpEF Patients
Active, not recruiting	`NCT05204238` - Follow Up of acuTe Heart failUre: a pRospective Echocardiographic and Clinical Study (FUTURE)
Completed	`NCT04535726` - The Relationship Between Blood Pressure and Arterial Stiffness in HFpEF Patients With Different Levels of Obesity
Recruiting	`NCT03550235` - Exploration of Dyspnea at Non-high Brain Natriuretic Peptide (BNP)
Completed	`NCT04633460` - Acute Effects of Exogenous Ketone Ester Administration in Heart Failure	Phase 2
Completed	`NCT06228807` - Clinical Characteristics and Predictors of Adverse Outcomes in HFpEF
Active, not recruiting	`NCT05284617` - Exploratory Ph 2A, Double-Blind, Placebo-Controlled Dose Escalation Study of Safety, Tolerability, PD, & PK of HU6 for Subjects With Obese HFpEF	Phase 2
Recruiting	`NCT05562063` - Sotagliflozin in Heart Failure With Preserved Ejection Fraction (HFpEF) Patients	Phase 4
Recruiting	`NCT06027307` - Enavogliflozin Outcome Trial in Functional Tricuspid Regurgitation	Phase 3
Recruiting	`NCT05582044` - Exercise Lower-body Negative Pressure in Heart Failure With Preserved Ejection Fraction	N/A